M
Mauricia Davidson
Researcher at Cochrane Collaboration
Publications - 5
Citations - 202
Mauricia Davidson is an academic researcher from Cochrane Collaboration. The author has contributed to research in topics: Medicine & Randomized controlled trial. The author has an hindex of 2, co-authored 2 publications receiving 33 citations. Previous affiliations of Mauricia Davidson include University of Paris.
Papers
More filters
Journal ArticleDOI
Interleukin-6 blocking agents for treating COVID-19: a living systematic review.
Lina Ghosn,Lina Ghosn,Anna Chaimani,Theodoros Evrenoglou,Mauricia Davidson,Mauricia Davidson,Carolina Graña,Carolina Graña,Christine Schmucker,Christine Schmucker,Claudia Bollig,Claudia Bollig,Nicholas Henschke,Yanina Sguassero,Camilla Hansen Nejstgaard,Camilla Hansen Nejstgaard,Sonia Menon,Sonia Menon,Thu Van Nguyen,Gabriel Ferrand,Gabriel Ferrand,Philipp Kapp,Philipp Kapp,Carolina Riveros,Carolina Riveros,Camila Ávila,Declan Devane,Declan Devane,Joerg J Meerpohl,Joerg J Meerpohl,Gabriel Rada,Asbjørn Hróbjartsson,Asbjørn Hróbjartsson,Giacomo Grasselli,Giacomo Grasselli,David Tovey,Philippe Ravaud,Philippe Ravaud,Isabelle Boutron,Isabelle Boutron +39 more
TL;DR: In this paper, the effect of interleukin 6 (IL-6) blocking agents compared to standard care alone or with placebo on efficacy and safety outcomes in severe coronavirus disease 2019 (COVID-19) was assessed.
Journal ArticleDOI
Efficacy and safety of COVID‐19 vaccines
Carolina Graña,Lina Ghosn,Theodoros Evrenoglou,Alexander Jarde,Silvia Minozzi,Hanna Bergman,Brian S Buckley,Katrin Probyn,Gemma Villanueva,Nicholas Henschke,H. Bonnet,Rouba Assi,Sonia Menon,Melanie Marti,Declan Devane,P. Mallon,Jean-Daniel Lelièvre,Lisa M. Askie,Tamara Kredo,Gabriel Ferrand,Mauricia Davidson,Carolina Riveros,David Tovey,Joerg J Meerpohl,Giacomo Grasselli,Gabriel Zada,Asbjørn Hróbjartsson,Philippe Ravaud,Anna Chaimani,Isabelle Boutron +29 more
TL;DR: In this paper , the authors evaluated the efficacy and safety of COVID-19 vaccines against SARS-CoV•2 virus and concluded that they probably reduce the risk of all-cause mortality (risk ratio (RR) 0.25, 95% CI 0.09 to 0.67.
Journal ArticleDOI
Interleukin-1 blocking agents for treating COVID-19.
Mauricia Davidson,Sonia Menon,Anna Chaimani,Theodoros Evrenoglou,Lina Ghosn,Carolina Graña,Nicholas Henschke,Elise Cogo,Gemma Villanueva,Gabriel Ferrand,Carolina Riveros,H. Bonnet,Philipp Kapp,Conor Moran,Declan Devane,Joerg J Meerpohl,Gabriel Zada,Asbjørn Hróbjartsson,Giacomo Grasselli,David Tovey,Philippe Ravaud,Isabelle Boutron +21 more
TL;DR: The effects of IL-1 blocking agents compared with standard care alone or with placebo on effectiveness and safety outcomes in people with COVID-19 are assessed and the certainty of evidence is rated using the GRADE approach for the critical outcomes of clinical improvement.
Journal ArticleDOI
Research response to coronavirus disease 2019 needed better coordination and collaboration: a living mapping of registered trials.
Van Thu Nguyen,Van Thu Nguyen,Philippe Rivière,Pierre Ripoll,Julien Barnier,Romain Vuillemot,Gabriel Ferrand,Sarah Cohen-Boulakia,Philippe Ravaud,Philippe Ravaud,Isabelle Boutron,Isabelle Boutron,Solaf Al-Awadhi,Sihem Amer-Yahia,Camila Ávila,Aïda Bafeta,Julia Baudry,Claudia Bollig,Hillary Bonnet,Marinette Bouet,Guillaume Cabanac,Anna Chaimani,Anna Chaimani,David Chavalarias,Yaolong Chen,Astrid Chevance,Emmanuel Coquery,Francoise Conil,Mauricia Davidson,Mauricia Davidson,Laura De Nale,Declan Devane,Elise Diard,Elise Diard,Bastien Doreau,Theodoros Evrenoglou,Theodoros Evrenoglou,Alice Fabri,Gilles Feron,Leopold Fezeu,Mathilde Fouet,Lina Ghosn El Chall,Lina Ghosn El Chall,Carolina Graña,Carolina Graña,Giacomo Grasselli,François Grolleau,Mohand-Said Hacid,Loubna Haddy,Camilla Hansen,Ameer Hohlfeld,Asbjørn Hróbjartsson,Chantal Julia,Dimitris Mavridis,Joerg J Meerpohl,Joerg J Meerpohl,Brice Meyer,Nivantha Naidoo,Nivantha Naidoo,Van Nguyen Thu,Van Nguyen Thu,Theodora Oikonomidi,Elizabeth D Pienaar,Fiona Quirke,Gabriel Rada,Gabriel Rada,Carolina Riveros,Carolina Riveros,Marie Sauvant,Christine Schmucker,Farouk Toumani,David Tovey,David Tovey,Jun Xia,Xuan Yu,Emina Zoletic,Pierre Zweigenbaum +76 more
TL;DR: This living mapping analysis showed that COVID-19 trials have relatively small sample size with certain redundancy in research questions, and most trials were registered when the first peak of the pandemic have passed.
Journal ArticleDOI
Interleukin-6 blocking agents for treating COVID-19: a living systematic review.
Lina Ghosn,Rouba Assi,Theodoros Evrenoglou,Brian S Buckley,Nicholas Henschke,Katrin Probyn,Carolina Riveros,Mauricia Davidson,Carolina Graña,H. Bonnet,Alexander Jarde,Camila Ávila,Camilla Hansen Nejstgaard,Sonia Menon,Gabriel Ferrand,Philipp Kapp,Claudia Breuer,Christine Schmucker,Yanina Sguassero,Thu Van Nguyen,Declan Devane,Joerg J Meerpohl,Gabriel Zada,Asbjørn Hróbjartsson,Giacomo Grasselli,David Tovey,Philippe Ravaud,Anna Chaimani,Isabelle Boutron +28 more
TL;DR: In this article , the effectiveness and safety of interleukin 6 (IL-6) blocking agents compared to standard care alone or to a placebo for people with COVID-19 was investigated.